Quantum-Si (NASDAQ:QSI) Issues Earnings Results

Quantum-Si (NASDAQ:QSI) announced its quarterly earnings results on Thursday. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.11), FiscalAI reports. The firm had revenue of $0.34 million during the quarter, compared to analysts’ expectations of $0.30 million. Quantum-Si had a negative net margin of 6,138.26% and a negative return on equity of 45.05%.

Here are the key takeaways from Quantum-Si’s conference call:

• Proteus launch delayed from the end of 2026 to the second quarter of 2027 as Quantum-Si adds an integrated instrument design cycle to improve repeatability, manufacturing yields, and product readiness.
• Management remains confident in the underlying sequencing technology and expects the additional development time could support launch detection of 19 or 20 amino acids, up from the previously planned 18.
• The company cited substantial market potential, including more than $4 billion annually in non-human proteomics and opportunities such as AAV serotyping, pathogen surveillance, and agricultural research; it has qualified more than 250 institutions interested in Proteus.
• Quantum-Si announced a targeted workforce reduction of approximately 20%, expected to generate about $12 million in annual operating expense savings and extend its cash runway into the fourth quarter of 2028.
• Second-quarter revenue fell to $344,000 from $591,000 a year earlier, while first-half revenue declined to $602,000 from $1.4 million; the company reiterated full-year 2026 revenue guidance of approximately $1 million.

Quantum-Si Stock Down 6.4%

Shares of NASDAQ QSI opened at $0.74 on Friday. Quantum-Si has a twelve month low of $0.69 and a twelve month high of $3.10. The firm has a fifty day simple moving average of $0.86 and a 200 day simple moving average of $0.93. The company has a market capitalization of $161.10 million, a PE ratio of -1.61 and a beta of 3.24.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on QSI. Alliance Global Partners reissued a “buy” rating on shares of Quantum-Si in a research note on Friday. Weiss Ratings cut Quantum-Si from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Quantum-Si currently has a consensus rating of “Hold” and a consensus target price of $1.00.

Institutional Trading of Quantum-Si

A number of large investors have recently bought and sold shares of QSI. Prudential Financial Inc. bought a new position in shares of Quantum-Si in the 2nd quarter worth about $25,000. Cerity Partners LLC bought a new stake in shares of Quantum-Si during the 2nd quarter valued at about $29,000. BNP Paribas Financial Markets grew its stake in Quantum-Si by 101.3% during the third quarter. BNP Paribas Financial Markets now owns 30,464 shares of the company’s stock worth $43,000 after purchasing an additional 15,331 shares during the period. Dimensional Fund Advisors LP bought a new stake in Quantum-Si in the fourth quarter worth approximately $34,000. Finally, State Board of Administration of Florida Retirement System bought a new stake in Quantum-Si in the fourth quarter worth approximately $45,000. 39.90% of the stock is currently owned by institutional investors and hedge funds.

Quantum-Si Company Profile

Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.

Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.